Sun Pharmaceutical Industries Limited and Philogen SpA announced Tuesday that they have entered into a licensing agreement to commercialize Philogen’s specialty product, Nidlegy (Daromun) in Europe, Australia and New Zealand.
Nidlegy, currently in Phase III clinical trials, is a novel anti-cancer biopharmaceutical being developed by Philogen for the treatment of melanoma and non-melanoma skin cancers.
Under the terms of the agreement, Sun Pharma will have exclusive rights to market Nidlegy in skin cancer indications in Europe, Australia and New Zealand.
Philogen will complete pivotal clinical trials for the product in Europe, pursue marketing authorization with regulatory authorities and produce commercial supplies. Sun Pharma will be responsible for commercialization activities, the company said in a press statement. The two partner companies will share the post-commercialization economics in a ratio of approximately 50:50. Other financial terms were not disclosed. Philogen retains IP rights to Nidlegy for areas and indications other than skin cancer.
“We are excited to partner with Philogen for Nidlegy, a new skin cancer immunotherapy treatment that is approaching market. This collaboration is in line with our goal of bringing innovative products to patients. With the anticipated addition of Nidlegy to our existing Odomzo franchise, we will be well positioned to provide patient solutions for a broad spectrum of skin cancers across multiple disease stages,” said Hellen De Kloet, Business Head – Western Europe and ANZ, Sun Pharma, said in a statement.
